Tolerance and pharmacokinetic interactions of rifabutin and azithromycin

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 5, 2001, Pages 1572-1577

  Hafner, R ^a   Bethel, J ^a   Standiford, H C ^a   Follansbee, S ^a   Cohn, D L ^a   Polk, R E ^a   Mole, L ^a   Raasch, R ^a   Kumar, P ^a   Mushatt, D ^a   Drusano, G ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; RIFABUTIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MULTICENTER STUDY; MYALGIA; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; TREATMENT PLANNING;

ADULT; AREA UNDER CURVE; AZITHROMYCIN; DRUG COMBINATIONS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; RIFABUTIN;

EID: 0035038017     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.5.1572-1577.2001     Document Type: Article

References (18)

1. Comparison of azithromycin and clarithromycin in their interactions with rifabutin in healthy volunteers
2. Disseminated Mycobacterium avium complex disease in patients with AIDS
3. Relationship of adverse events to serum drug levels in patients receiving high-dose azithromycin for mycobacterial lung disease
4. The impact of Mycobacterium avium complex bacteremia and its treatment on survival of AIDS patients - A prospective study
5. The pharmacokinetics of azithromycin in human serum and tissues
6. Varying dosages of rifabutin affect white blood cell and platelet counts in human immunodeficiency virus-negative patients who are receiving multidrug regimens for pulmonary Mycobacterium avium complex disease
7. Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers
8. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both
9. Survival of patients with acquired immune deficiency syndrome and disseminated Mycobacterium avium complex infection with and without antimycobacterial chemotherapy
10. Azithromycin as treatment for disseminated Mycobacterium avium complex in AIDS patients
11. A sensitive method for quantitation of rifabutin and its desacetyl metabolite in human biological fluids by high-performance liquid chromatography (HPLC)
12. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS
13. Once weekly azithromycin therapy for prevention of Mycobacterium avium complex infection in patients with AIDS: A randomized, double-blind, placebo-controlled multicenter trial
14. LAGRAN program for area and moments in pharmacokinetic analysis
15. High-performance liquid chromatographic assay with electrochemical detection for azithromycin in serum and tissues
16. Pharmacokinetics of rifabutin
17. Efficacy of rifabutin in the treatment of disseminated infection due to Mycobacterium avium complex
18. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus